You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Therapeutic DNA Epitope Vaccine for Alzheimer's Disease
SBC: ICHOR MEDICAL SYSTEMS, INC. Topic: N/AAlzheimer's disease (AD) is the most common form of dementia in the elderly. It is estimated that there are currently more than 18 million people worldwide with AD and this number is projected to nearly double by 2025 to 34 million. The enormous, increasing worldwide healthcare burden of AD and the lack of effective drugs indicate new prophylactic and/or therapeutic approaches for treating AD are ...
SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Molecular breast imaging to guide early-stage patient care
SBC: GAMMA MEDICA-IDEAS, INC. Topic: N/ADESCRIPTION (provided by applicant): Molecular Breast Imaging to Guide Early-Stage Patient Care Molecular Breast Imaging (MBI) will one day provide decision guidance for patient management without the need to perform a biopsy - that is without the need to cut out tissue that often is found to be normal. MBI's future benefit to women's health will obviate stressful watching and waiting periods of m ...
SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Retinal tissue derived from human pluripotent stem cells for vision restoration
SBC: BioTime, Inc. Topic: NEIAbstract from the original SBIR Phase II This project will test human embryonic stem cell derivedD retinal tissue transplanted in subretinal space ofanimal models with photoreceptorPRdegeneration in a longitudinal study lasting for up tomonthsWe will use a large eye animal model of early onset RD with a Crx mutationRdy Abyssinian catsand immunodeficient rats with PR degeneration SD FoxnTg SterLavR ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE
SBC: SIBTECH, INC. Topic: NCIThe overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vascula ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Automated Seizure Detection for Home Seizure Monitoring with Epilog Sensors
SBC: EPITEL, INC. Topic: 105ABSTRACT Aura is a digital health platform that uses Epilog™, a miniature, wireless, wearable EEG sensor worn on the scalp below hairline that can record clinical and subclinical seizures. After an initial diagnosis of epilepsy, an epileptologist will use known information about patients’ seizures to guide the best scalp location to place the Epilog EEG sensor (A). EEG data is continuously tra ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
N/A
SBC: AREA DETECTOR SYSTEMS CORPORATION Topic: N/ANot Available A new design approach is proposed for partial communication liquid acquisition devices (LADs) with window screens for cryogenic applications. These "start-basket" devices differ from total communication devices in that liquid is retained in an auxiliary
SBIR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health -
Near patient molecular diagnostics test for infections
SBC: GeneFluidics, Inc. Topic: RABSTRACT Currently there are no FDA cleared molecular based tests for urinary tract infection UTI pathogen identification and antimicrobial susceptibility testing to replace the andapos gold standardandapos of dipstick urinalysis and urine culturing All pathogen identification tests still rely on clinical isolates from urine cultures largely unchanged from Kochandapos s postulates developed ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome
SBC: MITOPOWER LLC Topic: 999Novel therapy for alcoholic liver disease-associated hepatorenal syndrome Abstract Alcoholic liver disease (ALD) results in over 400,000 hospitalizations each year in the US, with a portion of these patients developing hepatorenal syndrome with acute kidney injury (HRS-AKI). There are no current therapeutic options that specifically address the cellular dysfunction and systemic inflammatory respon ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Implantable Peripheral Nerve Stimulator for Treatment of Phantom Limb Pain
SBC: RIPPLE LLC Topic: 999Abstract Chronic phantom limb painPLPhas been reported to inflict as many asof people with amputationsPLP is described as feeling like burningtwistingitchingor pressure in part of the missing limbThese painful sensations have a substantial negative impact on quality of lifepeople who suffer PLP have high rates of depressiondifficulty sleepingregular absences from workdissociation with family frien ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeted Paraoxonase Fusion Protein as a Neurotherapeutic for Nerve Gas Agents
SBC: ARMAGEN TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): Civilian populations are at risk for exposure to chemical nerve gas agents such as organophosphates (OPs). These compounds affect both the peripheral nervous system (PNS) and the central nervous system (CNS). The CNS is affected because the OPs are lipid-soluble small molecules that easily penetrate the brain, owing to transport across the blood-brain barrier ( ...
SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health